THE PROGNOSTIC VALUE OF NUCLEAR VERSUS ARCHITECTURAL GRADING IN ENDOMETRIAL ADENOCARCINOMA - A GYNECOLOGIC-ONCOLOGY-GROUP STUDY

被引:45
|
作者
ZAINO, RJ
SILVERBERG, SG
NORRIS, HJ
BUNDY, BN
MORROW, CP
OKAGAKI, T
机构
[1] PENN STATE UNIV, MILTON S HERSHEY MED CTR, DEPT PATHOL, HERSHEY, PA 17033 USA
[2] GEORGE WASHINGTON UNIV, MED CTR, DIV ANAT PATHOL, WASHINGTON, DC 20037 USA
[3] ARMED FORCES INST PATHOL, DEPT GYNECOL & BREAST PATHOL, WASHINGTON, DC 20306 USA
[4] ROSWELL PK CANC INST, GYNECOL ONCOL GRP, BUFFALO, NY USA
[5] UNIV SO CALIF, SCH MED, DIV GYNECOL ONCOL, LOS ANGELES, CA 90033 USA
[6] UNIV MINNESOTA, SCH MED, MINNEAPOLIS, MN 55455 USA
关键词
ENDOMETRIUM; CARCINOMA; HISTOLOGIC GRADE;
D O I
10.1097/00004347-199401000-00004
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
The pathologic grade of endometrial adenocarcinoma is widely recognized as an important prognostic and therapeutic indicator. However, disagreement persists about the optimal method of determining grade. The pathology committee of the Gynecologic Oncology Group employs a system based on the proportion of tumor in glandular array; this system is both reproducible and predictive of outcome. Others have suggested that grading based on nuclear pleomorphism and the size of nucleoli provides better prognostication. We compared the three-level architectural grading system (AG) with a two-level nuclear grading system (NG) to determine reproducibility and prognostic value in 88 cases of stage 1 endometrial adenocarcinoma. Three pathologists made independent assessments of grade by each method. The division of tumors by architectural arrangement was superior for predicting survival (83%, 73%, and 44%, AG, p=0.005; vs. 79% and 61%, NG, p=0.14) and equivalent to nuclear grading for prediction of recurrence. Both systems were moderately reproducible (k=0.49, AG; k=0.57, NG). Assessment of NG was more tedious than that of AG. Subdivision of architectural grade based on high nuclear atypia, as recommended in current, International Federation of Gynecology and Obstetrics guidelines, did not improve prognostication. Because grading based on nuclear pleomorphism does not provide prognostic information superior to that resulting from architectural grading, we do not advocate its use in routine surgical pathology practice.
引用
收藏
页码:29 / 36
页数:8
相关论文
共 50 条
  • [1] THE PROGNOSTIC UTILITY OF NUCLEAR GRADING VERSUS ARCHITECTURAL GRADING IN ENDOMETRIAL ADENOCARCINOMA
    ZAINO, R
    SILVERBERG, S
    NORRIS, H
    BUNDY, B
    LABORATORY INVESTIGATION, 1992, 66 (01) : A70 - A70
  • [2] THE UTILITY OF THE REVISED INTERNATIONAL-FEDERATION-OF-GYNECOLOGY-AND-OBSTETRICS HISTOLOGIC GRADING OF ENDOMETRIAL ADENOCARCINOMA USING A DEFINED NUCLEAR GRADING SYSTEM - A GYNECOLOGIC-ONCOLOGY-GROUP STUDY
    ZAINO, RJ
    KURMAN, RJ
    DIANA, KL
    MORROW, CP
    CANCER, 1995, 75 (01) : 81 - 86
  • [3] PHASE-II EVALUATION OF DIANHYDROGALACTITOL IN THE TREATMENT OF ADVANCED ENDOMETRIAL ADENOCARCINOMA - A GYNECOLOGIC-ONCOLOGY-GROUP STUDY
    STEHMAN, FB
    BLESSING, JA
    DELGADO, G
    LOUKA, M
    CANCER TREATMENT REPORTS, 1983, 67 (7-8): : 737 - 738
  • [4] The prognostic value of nuclear grading and the revised FIGO grading of endometrial adenocarcinoma
    Ayhan, A
    Taskiran, C
    Yuce, K
    Kucukali, T
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL PATHOLOGY, 2003, 22 (01) : 71 - 74
  • [5] DNA content is an independent prognostic indicator in endometrial adenocarcinoma - A gynecologic oncology group study
    Zaino, RJ
    Davis, ATL
    Ohlsson-Wilhelm, BM
    Brunetto, VL
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL PATHOLOGY, 1998, 17 (04) : 312 - 319
  • [6] PROGNOSTIC FACTORS IN EARLY-STAGE UTERINE SARCOMA - A GYNECOLOGIC-ONCOLOGY-GROUP STUDY
    MAJOR, FJ
    BLESSING, JA
    SILVERBERG, SG
    MORROW, CP
    CREASMAN, WT
    CURRIE, JL
    YORDAN, E
    BRADY, MF
    CANCER, 1993, 71 (04) : 1702 - 1709
  • [7] TREATMENT OF ADVANCED OR RECURRENT ENDOMETRIAL CARCINOMA WITH MEDROXYPROGESTERONE ACETATE (MPA) - A GYNECOLOGIC-ONCOLOGY-GROUP STUDY
    THIGPEN, T
    BLESSING, J
    DISAIA, P
    EHRLICH, C
    GYNECOLOGIC ONCOLOGY, 1985, 20 (02) : 250 - 250
  • [8] ICRF-159 (RAZOXANE) IN PATIENTS WITH ADVANCED ADENOCARCINOMA OF THE ENDOMETRIUM - A GYNECOLOGIC-ONCOLOGY-GROUP STUDY
    HOMESLEY, HD
    BLESSING, JA
    CONROY, J
    HATCH, K
    DISAIA, PJ
    TWIGGS, LB
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 1986, 9 (01): : 15 - 17
  • [9] PHASE-II STUDY OF IFOSFAMIDE AND MESNA IN REFRACTORY ADENOCARCINOMA OF THE ENDOMETRIUM - A GYNECOLOGIC-ONCOLOGY-GROUP STUDY
    SUTTON, GP
    BLESSING, JA
    HOMESLEY, HD
    MCGUIRE, WP
    ADCOCK, L
    CANCER, 1994, 73 (05) : 1453 - 1455
  • [10] Grading of Lung Adenocarcinoma: Architectural Versus Nuclear Approach
    Deshpande, C. G.
    Geisinger, K.
    Petersen, I.
    Moreira, A.
    Zakowski, M.
    Shen, R.
    Suh, J.
    Motoi, N.
    Gerald, W.
    Kris, M.
    Rusch, V.
    Travis, W. D.
    LABORATORY INVESTIGATION, 2009, 89 : 352A - 352A